منابع مشابه
Inflammatory Cytokines and type 2 diabetes
Inflammatory cytokines increase in patients with type 2 diabetes (T2D) and metabolic syndrome. This review focuses on inflammatory cytokines such as C-reactive protein (CRP), tumor necrosis factor (TNF-α), and adiponectin, a cytokine produced by adipose tissue and associated with insulin sensitivity. Despite the major role of cytokines in the development of T2D, in the case of adiponectin still...
متن کاملPharmacogenomic approach in type 2 diabetes treatment
Introduction: Type 2 diabetes (T2D) is chronic health caused by the interaction between genetic and environmental factors that results in high blood glucose. The evidence-based guidelines for diabetes management are mainly based on lifestyle changes, control of risk factors, and the management of blood glucose levels. Although numerous antidiabetic agents have been developed over time, T2D trea...
متن کاملLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
BACKGROUND The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo. The primary composite outcome in the time-to-event analysis was the first oc...
متن کاملA1C and Cardiovascular Outcomes in Type 2 Diabetes
OBJECTIVE Type 2 diabetes is associated with increased cardiovascular risk. The role of aggressive glycemic control in preventing cardiovascular events is unclear. A nested case-control study design was used to evaluate the association between average A1C and cardiovascular outcomes. RESEARCH DESIGN AND METHODS Adults with type 2 diabetes were identified among members of Kaiser Permanente Sou...
متن کاملCardiovascular Outcomes with Empagliflozin – News for Type 2 Diabetes Therapy
Cardiovascular safety has to be proven for antidiabetic therapy for type 2 diabetes according to the guidance from regulatory bodies. Recently, the results of the respective study for the sodium-glucose transporter-2 (SGLT-2) inhibitor empagliflozin were published. Unlike similar studies for other antidiabetic agents that proved cardiovascular safety by non-inferiority compared with standard tr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Obesity Research
سال: 2002
ISSN: 1071-7323
DOI: 10.1038/oby.2002.185